Company profile
CINGULATE INC.
NASDAQ:CINGBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DEXMETHYLPHENIDATE | phase1_2 | — | 3 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04138498 | phase1_2 | completed | 2019-12-06 | 2020-03-06 | Cingulate Therapeutics | CTx-1301 Comparative Bioavailability Study |
| NCT04449250 | phase1 | completed | 2022-09-14 | 2022-10-14 | Cingulate Therapeutics | Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects |
| NCT07119073 | phase1 | completed | 2024-10-31 | 2024-12-21 | Cingulate Therapeutics | In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted) |
| NCT05286762 | phase3 | completed | 2023-08-01 | 2024-02-29 | Cingulate Therapeutics | Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 |
| NCT05924594 | phase3 | suspended | 2023-07-31 | 2027-02-01 | Cingulate Therapeutics | Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 |
FDA applications (0)
No records yet.